BETA
Your AI-Trained Oncology Knowledge Connection!
Dr Leleu on SC Isatuximab via On-Body Injector in R/R Multiple Myeloma
Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.
Read More
ASCO 2025: Dr Shepard on Advancing Cancer Care
Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.
Dr Hamilton: ASCO 2025 Breast Cancer Breakthroughs
Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.
Dr Abramson on ASCO 2025 DLBCL Updates: What's New?
Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.
Dr Morgans Provides Prostate Cancer Updates From ASCO 2025
Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical Oncology Annual Meeting: the AMPLITUDE trial.
Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689
A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.
Linvoseltamab/Carfilzomib Shows Promising Efficacy in Heavily Pretreated RRMM
Sacituzumab/Pembrolizumab Combo Shows Promise in Bladder Cancer
Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder cancer, enabling bladder preservation.
ENVISION: UGN-102 Shows Strong Response in Recurrent NMIBC
UGN-102 shows promising results in treating recurrent low-grade, intermediate-risk bladder cancer, with high response rates and manageable side effects.
Vepdegestrant Shows PFS Advantage in ESR1-Mutant ER+/HER2− Breast Cancer
Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.
Padeliporfin VTP Shows Promise for Low-Grade Upper Tract Urothelial Cancer
Interim results reveal padeliporfin VTP therapy as a promising, safe treatment for low-grade upper tract urothelial cancer, preserving kidney function.
BPd Combo Improves PFS & Response in High-Risk Relapsed/Refractory Myeloma
Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.
Nivolumab/Relatlimab Shows Intracranial Activity in Melanoma Brain Mets
Nivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.
Pembrolizumab Sets New Standard in Advanced Cervical Cancer Care
Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.
Cell-Free DNA: Revolutionizing Breast Cancer Management and Screening
Massimo Cristofanilli, MD, discusses the role of cell-free DNA in breast cancer.
Larotrectinib Shows Durable Responses, Safety in TRK Fusion Thyroid Carcinoma
An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.
Pharmacist-Led Initiatives Drive Cost Reduction in Oncology Care
Zipalertinib Offers Promising Oral Option for EGFR Exon 20+ NSCLC
Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.
RET Inhibitor Rechallenge: Efficacy in NSCLC After Discontinuation
A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.
RP1/Nivolumab Shows Systemic Activity in Advanced Melanoma
New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.
Epcoritamab Yields Durable Remissions in R/R LBCL at 2 Years
Epcoritamab shows promising long-term remission and survival rates for relapsed/refractory large B-cell lymphoma, highlighting its potential in advanced treatment settings.
Integrated Biomarkers Boost RCC Response Prediction
David A. Braun, MD, PhD, reveals how integrating tumor and circulating biomarkers enhances treatment response predictions in advanced renal cell carcinoma.
The Future of Rusfertide Research in Polycthemia Vera
FINER Trial: Ipatasertib Combo Extends PFS in ER+/HER2- Breast Cancer
Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.
Real-World Study Illuminates Waldenstrom Macroglobulinemia Outcomes
BNT327/Chemo Shows Durable Responses in Mesothelioma
A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.
Pembrolizumab Combo Promising for Unresectable Vulvar Cancer
A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.
THIO/Cemiplimab Combo Shows Activity in ICI-Resistant NSCLC
A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.
ICT01 Boosts AML Remission and Survival in EVICTION Trial
Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis